No Data
Eyez: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Eyez: Presentation of financial results for the 3rd quarter of the fiscal year ending 2024/12
Japan Postal Service, Japan Post Bank, Mizuho, Dai-ichi Life HD (14th) (5010-9994)
Please note that the above calendar is just a schedule and is subject to change due to company circumstances.--------------------------------------- November 14 (Thursday) <5010> Nippon Seiro <5027> AnyMind G <5029> Circlace <5033> Nulab <5034> unerry <5038> eWeLL <5074> Tes HD <5101>
TOPIX gross index rebounds, the increase narrows after a round of buying.
Tokyo Stock Exchange Growth Market Index 797.12 +4.14 / Volume 0.2 billion 43.61 million shares / Trading value 112.5 billion yen Tokyo Stock Exchange Growth Market 250 Index 621.45 +3.32 / Volume 74.25 million shares / Trading value 67.8 billion yen Today's growth market, both the Growth Market Index and the Growth Market 250 Index rebounded, with 300 gainers, 233 losers, and 54 unchanged. Today's growth market had a firm development. The Dow Jones Index of the U.S. market on the previous 5 days.
The Tokyo Stock Exchange Gross Market 250 Index significantly continued to decline, with little trading interest towards Metro businesses.
Tokyo Stock Exchange Growth Market Index 774.85 -12.83 / Volume 0.1 billion 53.45 million shares / Trading value 83.9 billion yen Tokyo Stock Exchange Growth Market 250 Index 604.09 -10.81 / Volume 86.73 million shares / Trading value 59.3 billion yen Today's Growth Market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, continued to decline significantly. The number of advancing stocks is 113, declining stocks is 437, unchanged is 36. The U.S. stock market on the 22nd had mixed performance. The Dow Jones Industrial Average fell by 6.71 dollars.
Emerging Markets Digest: Deere & Co soaring, BUYSELL plummeting
<219A> Heartseed 1515 rebounds by +51. Company announced an upward revision of financial estimates for the fiscal year ending October 24, with revenue increasing from 15.3 billion yen to 0.874 billion yen (an increase of 470.2%), and operating loss expected to decrease from a deficit of 1.965 billion yen to a deficit of 105.9 billion yen, narrowing the loss margin. Under an exclusive technical partnership and licensing agreement targeting the global market with novo-nordisk a/s, a major global pharmaceutical company, the development milestone expected for the fiscal year ending October 25 has been anticipated as of January 24.
No Data
No Data